✦ LIBER ✦

An open-label, multicenter, ascending dose study of the tolerability and safety of recombinant human acid sphingomyelinase (rhASM) in patients with ASM deficiency (ASMD)

✍ Scribed by Jones, Simon; Wasserstein, Melissa; Soran, Handrean; Breen, Catherine; Thurberg, Beth; Culm-Merdek, Kerry; Lippa, Natalie; Pimlott, Brenda; Cunningham, Andrew

Book ID: 122182363
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 55 KB
Volume: 111
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2013.12.124

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single- and Multiple-Dose Pharmacokineti

Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia

✍ Mitchell, Malcolm; Kothare, Prajakti; Bergstrom, Richard; Zhao, Fangyi; Jen, Kai 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 419 KB

A multicenter open-label phase I/II stud

A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis

✍ Der-Yuan Chen; Ning-Sheng Lai; Ling-Ying Lu; Hsiu-Cheng Chou; Yi-Hsing Chen; Tsu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 Chinese ⚖ 428 KB

Comparison of the efficacy and tolerabil

Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in korean patients with hypercholesterolemia

✍ Sang Hak Lee; Namsik Chung; Jun Kwan; Doo-Il Kim; Won Ho Kim; Chee Jeong Kim; Hy 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 627 KB

OR03-5 A phase 2, multicenter, multiple-

OR03-5 A phase 2, multicenter, multiple-dose, open-label, parallel-group, active controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study of ACP-001 in adult patients with Growth Hormone Deficiency (AGHD)

✍ Höybye, C.; Pfeiffer, A.F.H.; Ferone, D.; Gilfoyle, D.; Beckert, M.; Christianse 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Long Term Outcomes of a Phase 1/2, Multi

Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)

✍ Christian Hendriksz; Ashok Vellodi; Simon Jones; Hiwot Takkele; S. Lee; Sarah Ch 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

234 A phase 1, open-label, dose-finding

234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors

✍ P. LoRusso; V. Keedy; L. Yee; M. Oliveira; N. Rizvi; J. Berlin; X. Jin; T. Hettm 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 53 KB